COG-ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Objective

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

National Clinical Trial (NCT) Number: 03126916

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/ct2/show/NCT03126916

Location: Essentia Health Cancer Centers

Research Study Categories

• Pediatric Oncology Studies

Specialties

• Rare Tumor
• Brain Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]